{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/VKTX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T17:07:13.582Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9317,"canonical_name":"Viking Therapeutics, Inc.","cik":"0001607678","uei":null,"lei":null,"duns":null,"ticker":"VKTX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"clinical":4,"sec":25},"count":29,"timeline":[{"ts":"2026-10-09","kind":"clinical.trial","reporter":"Viking Therapeutics, Inc.","title":"Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07868939","excerpt":"[\"Weight Loss\"]","importance":60},{"ts":"2026-10-09","kind":"clinical.trial","reporter":"Viking Therapeutics, Inc.","title":"Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07868835","excerpt":"[\"Weight Loss\"]","importance":60},{"ts":"2026-09-29","kind":"clinical.trial","reporter":"Viking Therapeutics, Inc.","title":"A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07846033","excerpt":"[\"Obese Adults\"]","importance":30},{"ts":"2026-09-28","kind":"sec.filing","form_type":"8-K","title":"8-K — Viking Therapeutics, Inc. — 2026-09-28","url_slug":"/sec/cik-0001607678/8-k/0001193125-26-405580","accession_number":"0001193125-26-405580","importance":35},{"ts":"2026-09-25","kind":"sec.filing","form_type":"424B5","title":"424B5 — Viking Therapeutics, Inc. — 2026-09-25","url_slug":"/sec/cik-0001607678/424b5/0001193125-26-401384","accession_number":"0001193125-26-401384","importance":30},{"ts":"2026-09-25","kind":"sec.filing","form_type":"424B5","title":"424B5 — Viking Therapeutics, Inc. — 2026-09-25","url_slug":"/sec/cik-0001607678/424b5/0001193125-26-401385","accession_number":"0001193125-26-401385","importance":30},{"ts":"2026-09-24","kind":"sec.filing","form_type":"305B2","title":"305B2 — Viking Therapeutics, Inc. — 2026-09-24","url_slug":"/sec/cik-0001607678/305b2/0001213900-26-102782","accession_number":"0001213900-26-102782","importance":30},{"ts":"2026-09-24","kind":"sec.filing","form_type":"FWP","title":"FWP — Viking Therapeutics, Inc. — 2026-09-24","url_slug":"/sec/cik-0001607678/fwp/0001213900-26-102798","accession_number":"0001213900-26-102798","importance":30},{"ts":"2026-09-24","kind":"clinical.trial","reporter":"Viking Therapeutics, Inc.","title":"A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07838740","excerpt":"[\"Obese Adults\"]","importance":30},{"ts":"2026-09-23","kind":"sec.filing","form_type":"424B5","title":"424B5 — Viking Therapeutics, Inc. — 2026-09-23","url_slug":"/sec/cik-0001607678/424b5/0001193125-26-399627","accession_number":"0001193125-26-399627","importance":30},{"ts":"2026-09-23","kind":"sec.filing","form_type":"424B5","title":"424B5 — Viking Therapeutics, Inc. — 2026-09-23","url_slug":"/sec/cik-0001607678/424b5/0001193125-26-399628","accession_number":"0001193125-26-399628","importance":30},{"ts":"2026-09-22","kind":"sec.filing","form_type":"8-K","title":"8-K — Viking Therapeutics, Inc. — 2026-09-22","url_slug":"/sec/cik-0001607678/8-k/0001193125-26-397219","accession_number":"0001193125-26-397219","importance":35},{"ts":"2026-08-07","kind":"sec.filing","form_type":"3","title":"3 — Viking Therapeutics, Inc. — 2026-08-07","url_slug":"/sec/cik-0001607678/3/0002144542-26-000003","accession_number":"0002144542-26-000003","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"4","title":"4 — Viking Therapeutics, Inc. — 2026-08-07","url_slug":"/sec/cik-0001607678/4/0002144542-26-000004","accession_number":"0002144542-26-000004","importance":30},{"ts":"2026-07-30","kind":"sec.filing","form_type":"S-3ASR","title":"S-3ASR — Viking Therapeutics, Inc. — 2026-07-30","url_slug":"/sec/cik-0001607678/s-3asr/0001193125-26-324455","accession_number":"0001193125-26-324455","importance":30},{"ts":"2026-07-29","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Viking Therapeutics, Inc. — 2026-07-29","url_slug":"/sec/cik-0001607678/10-q/0001193125-26-324219","accession_number":"0001193125-26-324219","importance":45},{"ts":"2026-07-29","kind":"sec.insider.s","reporter":"Lian Brian","title":"President & CEO","shares":148517,"price_per_share":33.3153,"usd_value":4947888,"security_title":"Common Stock, par value $0.00001 per share","importance":39.9478884101},{"ts":"2026-07-29","kind":"sec.insider.s","reporter":"ZANTE GREG","title":"Chief Financial Officer","shares":21217,"price_per_share":33.4704,"usd_value":710141,"security_title":"Common Stock, par value $0.00001 per share","importance":35.7101414768},{"ts":"2026-07-29","kind":"sec.insider.s","reporter":"Mancini Marianna","title":"Chief Operating Officer","shares":18217,"price_per_share":33.4652,"usd_value":609636,"security_title":"Common Stock, par value $0.00001 per share","importance":35.6096355484},{"ts":"2026-07-29","kind":"sec.filing","form_type":"8-K","title":"8-K — Viking Therapeutics, Inc. — 2026-07-29","url_slug":"/sec/cik-0001607678/8-k/0001193125-26-323652","accession_number":"0001193125-26-323652","importance":35},{"ts":"2026-07-29","kind":"sec.filing","form_type":"144","title":"144 — Viking Therapeutics, Inc. — 2026-07-29","url_slug":"/sec/cik-0001607678/144/0001950047-26-007376","accession_number":"0001950047-26-007376","importance":30},{"ts":"2026-07-29","kind":"sec.filing","form_type":"144","title":"144 — Viking Therapeutics, Inc. — 2026-07-29","url_slug":"/sec/cik-0001607678/144/0001950047-26-007394","accession_number":"0001950047-26-007394","importance":30},{"ts":"2026-07-29","kind":"sec.filing","form_type":"4","title":"4 — Viking Therapeutics, Inc. — 2026-07-29","url_slug":"/sec/cik-0001607678/4/0001193125-26-324446","accession_number":"0001193125-26-324446","importance":30},{"ts":"2026-07-29","kind":"sec.filing","form_type":"4","title":"4 — Viking Therapeutics, Inc. — 2026-07-29","url_slug":"/sec/cik-0001607678/4/0001193125-26-324448","accession_number":"0001193125-26-324448","importance":30},{"ts":"2026-07-28","kind":"sec.insider.a","reporter":"ZANTE GREG","title":"Chief Financial Officer","shares":31667,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, par value $0.00001 per share","importance":15},{"ts":"2026-07-28","kind":"sec.insider.a","reporter":"Mancini Marianna","title":"Chief Operating Officer","shares":31667,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, par value $0.00001 per share","importance":15},{"ts":"2026-07-28","kind":"sec.insider.a","reporter":"Lian Brian","title":"President & CEO","shares":221667,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, par value $0.00001 per share","importance":15},{"ts":"2026-06-03","kind":"sec.filing","form_type":"3","title":"3 — Viking Therapeutics, Inc. — 2026-06-03","url_slug":"/sec/cik-0001607678/3/0001193125-26-256038","accession_number":"0001193125-26-256038","importance":30},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Viking Therapeutics, Inc. — 2026-06-03","url_slug":"/sec/cik-0001607678/4/0001193125-26-256039","accession_number":"0001193125-26-256039","importance":30}]}